Search results for "angiotensin-converting enzyme inhibitor"

showing 10 items of 93 documents

How ineffective hypertension control in subjects treated with angiotensin-converting enzyme inhibitors is related to polymorphisms in the renin-angio…

2009

Abstract Purpose To investigate how genetic polymorphisms of the renin-angiotensin-aldosterone system (RAAS) influence hypertension (HT) control with angiotensin-converting enzyme inhibitor drugs (ACEI). Methods A case–control, cross-sectional population-based nested study (n = 1514) included hypertensive patients treated with ACEI drugs, either alone or with other antihypertensive drugs. We differentiated between those who did not control their HT (cases) with those who did (controls). Each group's characteristics were compared to determine the risk of non-controlled HT associated with RAAS polymorphisms by adjusting for different variables. Results rs11571074 obtained an ORa of 5.26 for T…

AdultMalemedicine.medical_specialtyAdolescentPopulationPharmaceutical ScienceAngiotensin-Converting Enzyme InhibitorsPharmacologyYoung AdultPolymorphism (computer science)Internal medicineRenin–angiotensin systemGenotypemedicineHumanseducationAgedAged 80 and overeducation.field_of_studyPolymorphism GeneticHypertension controlbiologybusiness.industryCase-control studyAngiotensin-converting enzymeMiddle AgedEndocrinologyCross-Sectional StudiesCase-Control StudiesACE inhibitorHypertensionbiology.proteinFemalebusinessmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.

2001

To determine the antihypertensive efficacy, effect duration and safety of the angiotensin II type 1 receptor blocker candesartan cilexetil and the angiotensin converting enzyme inhibitor enalapril once daily in patients with mild to moderate hypertension.A multicenter, randomised, double-blind parallel group study was performed in Finland, France, the Netherlands, Spain and Sweden. Three-hundred-and-ninety-five men and women in the age range 20-80 years with primary hypertension were randomised to an 8-week double-blind treatment period with either candesartan cilexetil 8-16 mg or enalapril 10-20 mg once daily, with forced dose titration after 4 weeks. Non-invasive ambulatory blood pressure…

AdultMalemedicine.medical_specialtyAmbulatory blood pressureTime Factorsmedicine.medical_treatmentDiastoleTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood PressureAngiotensin Receptor AntagonistsDouble-Blind MethodEnalaprilHeart RateInternal medicineInternal MedicinemedicineHumansProdrugsEnalaprilAntihypertensive AgentsAgedAged 80 and overChemotherapybiologybusiness.industryBiphenyl CompoundsAngiotensin-converting enzymeGeneral MedicineMiddle AgedAngiotensin IICandesartanEndocrinologyTherapeutic EquivalencyACE inhibitorHypertensionbiology.proteinCardiologyBenzimidazolesFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugBlood pressure
researchProduct

Sexual dysfunction in hypertensive patients treated with losartan.

2001

ABSTRACT Background Impaired erectile function in men is a component of the dysmetabolic syndrome of high blood pressure as well as a sequela of antihypertensive therapy. This prospective interventional study in men with uncontrolled hypertension (blood pressure ≥ 140/90 mm Hg) used a survey instrument to assay sexual dysfunction before and after therapy with losartan. Methods We evaluated the influence of a 12-week therapy with losartan in 82 hypertensive subjects with (n = 82) and without (n = 82) a diagnosis of erectile dysfunction using a self-administered questionnaire validated in another 60 subjects with hypertension. Results: From an initial sample of 323 hypertensive men and women,…

AdultMalemedicine.medical_specialtyAngiotensin-Converting Enzyme InhibitorsLosartanInternal medicinemedicineHumansProspective StudiesSexual Dysfunctions PsychologicalProspective cohort studyDiureticsAntihypertensive AgentsAgedbusiness.industrySequelaGeneral MedicineMiddle Agedmedicine.diseaseSurgeryRegimenBlood pressureErectile dysfunctionLosartanSexual dysfunctionHypertensionFemalemedicine.symptombusinessSexual functionmedicine.drugThe American journal of the medical sciences
researchProduct

Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension

2004

The objective was to study factors related to the changes induced by antihypertensive treatment on oxidative status, antioxidant activities, and reactive oxygen species by-products in whole blood and mononuclear peripheral cells. Eighty-nine hypertensive patients (mean age 46 years, 46 men, average 24-h blood pressure 139/88 mm Hg, body mass index 29) were included. After 3 months of nonrandomized allocation to antihypertensive treatment (20 nonpharmacologic, 36 beta-blockers, 33 angiotensin receptor blocker), oxidized/reduced glutathione ratio and malondialdehyde were significantly reduced, and the activity of superoxide dismutase, catalase, and glutathione peroxidase was significantly inc…

AdultMalemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentAngiotensin-Converting Enzyme Inhibitorsmedicine.disease_causeBenzoatesAntioxidantsSuperoxide dismutasechemistry.chemical_compoundInternal medicineInternal MedicinemedicineHumansTelmisartanAntihypertensive AgentsWhole bloodchemistry.chemical_classificationReactive oxygen speciesbiologybusiness.industryGlutathione peroxidaseGlutathioneMiddle AgedMalondialdehydeOxidative StressHydrochlorothiazideTreatment OutcomeEndocrinologyAtenololchemistryHypertensionbiology.proteinBenzimidazolesDrug Therapy CombinationFemalebusinessOxidative stressDNA DamageAmerican Journal of Hypertension
researchProduct

Screening for congenital renovascular hypoplasia and renal artery stenosis by acute converting enzyme inhibition.

1993

To evaluate the usefulness of the captopril test for identifying renal artery stenosis (RAS) and renovascular hypoplasia (RAH), we studied 48 hypertensive patients. In 20 hypertensives with screening procedures indicating renovascular disease and in 28 essential hypertensives (EH), the plasma renin activity (PRA) responses to an oral test dose of captopril (50 mg) were studied. A 60-min post-captopril PRA increase of 150% (or 400% if baseline PRA < or = 3 ng/ml/h) was considered as positive. Renal angiography was performed in all cases. Among the 20 renovascular hypertensive patients, RAH in 9 and RAS in 11 subjects were proved by angiography. The captopril test in all patients with RAH res…

AdultMalemedicine.medical_specialtyCaptoprilAdolescentUrologyAdministration OralAngiotensin-Converting Enzyme Inhibitorsurologic and male genital diseasesRenal artery stenosisKidneyRenal Artery ObstructionPlasma renin activityDiagnosis DifferentialRenin-Angiotensin SystemInternal medicinemedicine.arteryReninmedicineHumansRenal arteryScreening proceduresAgedKidneybusiness.industryKidney metabolismCaptoprilMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsHypoplasiaRadiographymedicine.anatomical_structureEndocrinologyHypertension RenovascularFemaleKidney Diseasesbusinesshormones hormone substitutes and hormone antagonistscirculatory and respiratory physiologymedicine.drugNephron
researchProduct

Angiotensin converting enzyme has an inhibitory role in CGRP metabolism in human skin

2005

The neutral endopeptidase (NEP) is important for calcitonin gene related peptide (CGRP) degradation, while the role of angiotensin converting enzyme (ACE) remains unclear. By using dermal microdialysis we explored the effect of phosphoramidon (NEP blocker), captopril (ACE blocker) and a mixture of both drugs on the intensity of electrically-induced CGRP-mediated neurogenic flare. The results reveal that phosphoramidon elevated flare intensity, but that this was not further increased by adding captopril. In contrast, neurogenic flare was decreased when the drug mixture was applied in compared to NEP only. Electrically released CGRP levels could be measured directly in perfusates containing p…

AdultMalemedicine.medical_specialtyCaptoprilPhysiologyCalcitonin Gene-Related PeptideNeuropeptideAngiotensin-Converting Enzyme InhibitorsPeptidyl-Dipeptidase ACalcitonin gene-related peptideBiochemistryCellular and Molecular Neurosciencechemistry.chemical_compoundEndocrinologyInternal medicineRetrograde DegenerationLaser-Doppler FlowmetrymedicineHumansNeprilysinSkinintegumentary systembiologyChemistryCatabolismfungiPhosphoramidonGlycopeptidesAngiotensin-converting enzymeCaptoprilMetabolismrespiratory systemVasodilationEndocrinologybiology.proteinFemalemedicine.drugPeptides
researchProduct

Factors Related to the Occurrence of Microalbuminuria During Antihypertensive Treatment in Essential Hypertension

2002

The objective of the study was to assess the factors related to the occurrence of microalbuminuria during the follow-up of a young adult group with essential hypertension that had not been previously treated. Normo-albuminuric essential hypertensives, &lt;50 years old, who had not been previously treated with antihypertensive drugs and who did not have diabetes mellitus were included. After the initial evaluation, patients were treated using only nonpharmacological measures (n=62), β-blockers (n=38), ACE inhibitors (n=64), calcium channel blockers (n=8), and several classes (n=15). Measurements were taken for office blood pressure, biochemical profile, and 24-hour urinary albumin excretion…

AdultMalemedicine.medical_specialtyNifedipineAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsEssential hypertensionEnalaprilLisinoprilRisk FactorsInternal medicineInternal MedicinemedicineAlbuminuriaBisoprololHumansYoung adultAntihypertensive AgentsProportional Hazards ModelsProteinuriabusiness.industryFollow up studiesMiddle AgedCalcium Channel Blockersmedicine.diseaseTreatment OutcomeEndocrinologyBlood pressureAtenololHypertensionAlbuminuriaRegression AnalysisFemaleMicroalbuminuriamedicine.symptombusinessPreviously treatedHypertension
researchProduct

Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study.

2006

The objective of the present study was to assess factors related to long-term changes in urinary albumin excretion (UAE) of nondiabetic microalbuminuric (n = 252) or proteinuric hypertensive individuals (n = 58) in a prospective follow-up.After enrollment, patients were placed on usual care including nonpharmacological treatment and/or treatment with an antihypertensive drug regime to achieve blood pressure135/85 mmHg. Periodic UAE measurements were performed until regression or significant reduction (defined when UAE dropped50% from the initial values, plus reduction of UAE to30 mg/24 h for microalbuminuric patients and300 mg/24 h for proteinuric patients).Among the microalbuminuric patien…

AdultMalemedicine.medical_specialtyPhysiologymedicine.drug_classAdrenergic beta-AntagonistsUrologyRenal functionAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionExcretionInternal medicineInternal MedicinemedicineAlbuminuriaHumansAntihypertensive drugbusiness.industryProportional hazards modelHazard ratioMiddle Agedmedicine.diseaseCalcium Channel BlockersConfidence intervalEndocrinologyBlood pressureHypertensionFemaleCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor BlockersFollow-Up StudiesGlomerular Filtration RateJournal of hypertension
researchProduct

Effects of cilazapril on renal haemodynamics and function in hypertensive patients: a randomised controlled study versus hydrochlorothiazide.

1995

In this study the efficacy and safety of short-term cilazapril administration on renal haemodynamics were evaluated in mild to moderate hypertensive subjects. Our final goal was to evaluate whether the reduction in blood pressure achieved by treatment was associated with maintained renal function. After a run-in period with placebo, 40 hypertensive subjects without renal or cardiac diseases were randomly allocated to a double-blind 4 week controlled trial with cilazapril 5 mg once a day (20 patients) or hydrochlorothiazide 25 mg once a day (20 patients). Renal haemodynamics measurements included effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) by radionuclide study us…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaUrologyRenal functionAngiotensin-Converting Enzyme InhibitorsCilazaprilEssential hypertensionRenal CirculationHydrochlorothiazideDouble-Blind MethodInternal medicineInternal MedicinemedicineAngiotensin-Converting Enzyme InhibitorsAntihypertensive Agents Hydrochlorothiazide CilazaprilHumansAntihypertensive AgentsAgedRenal circulationbusiness.industryHemodynamicsGeneral MedicineEffective renal plasma flowCilazaprilMiddle Agedmedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolareFiltration fractionmedicine.anatomical_structureEndocrinologyHydrochlorothiazideTreatment OutcomeRenal blood flowHypertensionSettore BIO/14 - FarmacologiaFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugGlomerular Filtration RateBlood pressure
researchProduct

Body weight changes and the A-6G polymorphism of the angiotensinogen gene

2002

BACKGROUND: The objective of the study was to analyze the relationship of polymorphisms of the angiotensinogen gene with changes in body weight during 3 y of antihypertensive treatment, in a group of young adults with essential hypertension. METHODS: Essential hypertensives, less than 50 y old, never previously treated with antihypertensive drugs and in the absence of diabetes mellitus were included. After the initial evaluation, patients were treated using only non-pharmacological measures (n=29), β-blockers (n=40) or angiotensin-converting enzyme inhibitors (n=66). Resting blood pressure, biochemical profile and body weight at the beginning and yearly were measured. The polymorphism A-6G …

AdultMalemedicine.medical_specialtyTime FactorsGenotypeEndocrinology Diabetes and MetabolismAdrenergic beta-AntagonistsAngiotensinogenMedicine (miscellaneous)Angiotensin-Converting Enzyme InhibitorsEssential hypertensionBody Mass IndexGene FrequencyPolymorphism (computer science)Diabetes mellitusInternal medicineGenotypeHumansMedicineAllele frequencyAntihypertensive AgentsAnalysis of VariancePolymorphism GeneticNutrition and Dieteticsbusiness.industryBody WeightMiddle Agedmedicine.diseaseBlood pressureEndocrinologyHypertensionFemalemedicine.symptombusinessBody mass indexWeight gainFollow-Up StudiesInternational Journal of Obesity
researchProduct